The National Pregnancy Registry for Antidepressants (NPRAD) is dedicated to evaluating the safety of antidepressant medications that may be taken by women during pregnancy to treat a wide range of mood, anxiety, or psychiatric disorders. The goal of this Registry is to gather information on the safety of these medications during pregnancy for both mother and child.
TO PARTICIPATE CALL TOLL-FREE: 1-866-961-2388
All pregnant women between the ages of 18-45 with a history of psychiatric illness are eligible to enroll in the registry. If you are interested in participating in the National Pregnancy Registry, please call the toll-free number above or fill out this Patient Interest Form to be contacted by a member of our research team. All information is kept strictly confidential.
More Information and Enrollment:
Required Sponsorship Disclosures:
Current Sponsors: Alkermes, Inc. (2016-Present); Otsuka America Pharmaceutical, Inc. (2008-Present); Sage Therapeutics (2019-Present); Sunovion Pharmaceuticals, Inc. (2011-Present); Teva Pharmaceutical Industries Ltd. (2018-Present).
Past Sponsors: Forest/Actavis (2016-2018, declined to sponsor: 2018-Present), AstraZeneca Pharmaceuticals (2009-2014, declined to sponsor: 2014-Present); Ortho-McNeil-Janssen Pharmaceuticals, Inc (2009-2014, declined to sponsor: 2015-Present); Pfizer, Inc. (2009-2011, declined to sponsor: 2012-Present)
Declined to sponsor: Eli Lilly and Company; Novartis Pharmaceuticals; Vanda Pharmaceuticals Inc.
Funding Information: Manufacturers of psychiatric medications have been approached regarding funding of the National Pregnancy Registry. Regardless of which entities have supported this initiative, all medications in this class are studied. For more information on how to sponsor the Registry, please see the contact information below.